1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab)...
1. A multicenter randomized control trial concluded that n-3 polyunsaturated fatty acid supplementation in pregnancy did not change the risk...
1. This phase 2, parallel-group randomized control trial compared the safety and efficacy profile of maribavir versus valgancicvlovir among patients...
1. The SENSCIS trial, a randomized control trial studying the efficacy of nintedanib, an intracellular tyrosine kinase inhibitor, versus placebo...
1. Two complementary phase 3 clinical trials randomized patients with moderate-to-severe COPD to receive either benralizumab or a placebo and...
1. Women with early pregnancy bleeding administered progesterone experienced similar rates of live births occurring after 34 weeks’ gestation as...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve...
1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression...
1. A randomized control trial of adult ICU patients randomized to receive either adjunct intermittent pneumatic compression with pharmacologic thromboprophylaxis...
1. HCV-naive patients in need of heart or lung transplants who received organs from HCV-positive donors and were treated with...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.